Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

697 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Gardner RA, et al. Among authors: summers c. Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13. Blood. 2017. PMID: 28408462 Free PMC article. Clinical Trial.
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
Summers C, Wu QV, Annesley C, Bleakley M, Dahlberg A, Narayanaswamy P, Huang W, Voutsinas J, Brand A, Leisenring W, Jensen MC, Park JR, Gardner RA. Summers C, et al. Transplant Cell Ther. 2022 Jan;28(1):21-29. doi: 10.1016/j.jtct.2021.10.003. Epub 2021 Oct 10. Transplant Cell Ther. 2022. PMID: 34644605 Free article. Clinical Trial.
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.
Ceppi F, Wilson AL, Annesley C, Kimmerly GR, Summers C, Brand A, Seidel K, Wu QV, Beebe A, Brown C, Mgebroff S, Lindgren C, Rawlings-Rhea SD, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA. Ceppi F, et al. Among authors: summers c. Cancer Immunol Res. 2022 Jul 1;10(7):856-870. doi: 10.1158/2326-6066.CIR-21-0501. Cancer Immunol Res. 2022. PMID: 35580141 Free PMC article. Clinical Trial.
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia.
Lamble AJ, Moskop A, Pulsipher MA, Maude SL, Summers C, Annesley C, Baruchel A, Gore L, Amrolia P, Shah N. Lamble AJ, et al. Among authors: summers c. Transplant Cell Ther. 2023 Nov;29(11):674-684. doi: 10.1016/j.jtct.2023.08.030. Epub 2023 Sep 9. Transplant Cell Ther. 2023. PMID: 37689393 Free article. Review.
Feasibility and Favorable Responses Following Investigational CAR T-Cell Therapy for Relapsed and Refractory Infant ALL.
Annesley C, Lamble AJ, Summers C, Pulsipher MA, Wayne AS, Rivers J, Huang W, Wilson A, Wu Q, Seidel KD, Mgebroff S, Brown CT, Lindgren C, Park JR, Jensen MC, Gardner RA. Annesley C, et al. Among authors: summers c. Blood Adv. 2024 Aug 12:bloodadvances.2024012638. doi: 10.1182/bloodadvances.2024012638. Online ahead of print. Blood Adv. 2024. PMID: 39133891
697 results